GlaxoSmithKline is acquiring California biopharmaceutical firm Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
Sierra Oncology Inc. announced that the clinical-stage drug-development company acquired the drug candidate momelotinib from Gilead Sciences.
